CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma--The Progress and the Limitations.
Publication
, Journal Article
Mar, N; Desjardins, A; Vredenburgh, JJ
Published in: Clin Cancer Res
October 1, 2015
Vredenburgh and colleagues conducted the first phase II study of bevacizumab plus irinotecan in recurrent malignant glioma, confirming the safety and efficacy of bevacizumab. This study, which was published in the February 15, 2007, issue of Clinical Cancer Research, was a stepping stone for subsequent research, leading to regulatory approval of bevacizumab for recurrent glioblastoma.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Clin Cancer Res
DOI
EISSN
1557-3265
Publication Date
October 1, 2015
Volume
21
Issue
19
Start / End Page
4248 / 4250
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- Neoplasm Recurrence, Local
- Male
- Humans
- Glioma
- Female
- Brain Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Mar, N., Desjardins, A., & Vredenburgh, J. J. (2015). CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma--The Progress and the Limitations. Clin Cancer Res, 21(19), 4248–4250. https://doi.org/10.1158/1078-0432.CCR-15-1381
Mar, Nataliya, Annick Desjardins, and James J. Vredenburgh. “CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma--The Progress and the Limitations.” Clin Cancer Res 21, no. 19 (October 1, 2015): 4248–50. https://doi.org/10.1158/1078-0432.CCR-15-1381.
Mar N, Desjardins A, Vredenburgh JJ. CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma--The Progress and the Limitations. Clin Cancer Res. 2015 Oct 1;21(19):4248–50.
Mar, Nataliya, et al. “CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma--The Progress and the Limitations.” Clin Cancer Res, vol. 21, no. 19, Oct. 2015, pp. 4248–50. Pubmed, doi:10.1158/1078-0432.CCR-15-1381.
Mar N, Desjardins A, Vredenburgh JJ. CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma--The Progress and the Limitations. Clin Cancer Res. 2015 Oct 1;21(19):4248–4250.
Published In
Clin Cancer Res
DOI
EISSN
1557-3265
Publication Date
October 1, 2015
Volume
21
Issue
19
Start / End Page
4248 / 4250
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- Neoplasm Recurrence, Local
- Male
- Humans
- Glioma
- Female
- Brain Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences